# US 2022/0033512 A1 · Inhibiting anti-enpp1 antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033512 A1
- Document ID: US20220033512A1
- Status: Published application
- Kind: A1
- Application number: 17/306,544
- Filed: 2021-05-03
- Published: 2022-02-03
- Earliest claimed: 2020-05-04
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Arjun Deb
- Web page: https://patentgrep.com/patent/US20220033512A1

## CPC

- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C07K 16/40: against enzymes
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In certain aspects, provided herein are inhibitory anti-ENPP1 antibodies and antigen binding fragments thereof. In some aspects, provided herein are methods of treating myocardial infarction using the antibodies provided herein. In certain aspects, provided herein are nucleic acid molecules encoding the antibodies provided herein, host cells comprising such nucleic acids, and methods of making the antibodies provided herein using such host cells. In some aspects, also provided herein are pharmaceutical compositions comprising the antibodies provided herein.

## Claims

### Claim 1

An antibody, or antigen-binding fragment thereof, comprising:
a) a heavy chain variable region sequence with at least about 95% sequence identity to a heavy chain variable region sequence listed in Table 2, Table 4, or Table 6; and/or
b) a light chain sequence with at least about 95% identity to a light chain variable region sequence listed in Table 2, Table 4, or Table 6.

### Claim 2

An antibody, or antigen-binding fragment thereof, comprising a heavy chain CDRH3 sequence of SEQ ID NO: 6, SEQ ID NO: 16, or SEQ ID NO: 26.

### Claim 3 (depends on 2)

The antibody of claim 2, further comprising a heavy chain CDRH1 sequence of SEQ ID NO: 4, SEQ ID NO: 14, or SEQ ID NO: 24.

### Claim 4 (depends on 2, 3)

The antibody of claim 2 or claim 3, further comprising a heavy chain CDRH2 sequence of SEQ ID NO: 5, SEQ ID NO: 15, or SEQ ID NO: 25.

### Claim 5 (depends on 2, 3, 4)

The antibody of any one of claims 2 to 4, further comprising a light chain CDRL3 sequence of SEQ ID NO: 3, SEQ ID NO: 13, or SEQ ID NO: 23.

### Claim 6 (depends on 2, 3, 4, 5)

The antibody of any one of claims 2 to 5, further comprising a light chain CDRL1 sequence of SEQ ID NO: 1, SEQ ID NO: 11, or SEQ ID NO: 21.

### Claim 7 (depends on 2, 3, 4, 5, 6)

The antibody of any one of claims 2 to 6, further comprising a light chain CDRL2 sequence of SEQ ID NO: 2, SEQ ID NO: 12, or SEQ ID NO: 22.

### Claim 8

An antibody, or antigen-binding fragment thereof, comprising:
a) a heavy chain comprising a CDRH1 of SEQ ID NO: 4, a CDRH2 of SEQ ID NO: 5, and a CDRH3 of SEQ ID NO: 6; and
b) a light chain comprising a CDRL1 of SEQ ID NO: 1, a CDRL2 of SEQ ID NO: 2, and a CDRL3 of SEQ ID NO: 3.

### Claim 9 (depends on 8)

The antibody of claim 8, comprising:
i) a heavy chain variable region sequence with at least 95% identity to SEQ ID NO: 7; and
ii) a light chain variable region sequence with at least 95% identity to SEQ ID NO: 9.

### Claim 10 (depends on 8)

The antibody of claim 8, comprising:
i) a heavy chain variable region sequence of SEQ ID NO: 7; and
ii) a light chain variable region sequence of SEQ ID NO: 9.

### Claim 11

An antibody, or antigen-binding fragment thereof, comprising:
a) a heavy chain comprising a CDRH1 of SEQ ID NO: 14, a CDRH2 of SEQ ID NO: 15, and a CDRH3 of SEQ ID NO: 16; and
b) a light chain comprising a CDRL1 of SEQ ID NO: 11, a CDRL2 of SEQ ID NO: 12, and a CDRL3 of SEQ ID NO: 13.

### Claim 12 (depends on 11)

The antibody of claim 11, comprising:
i) a heavy chain variable region sequence with at least 95% identity to SEQ ID NO: 17; and
ii) a light chain variable region sequence with at least 95% identity to SEQ ID NO: 19.

### Claim 13 (depends on 11)

The antibody of claim 11, comprising:
i) a heavy chain variable region sequence of SEQ ID NO: 17; and
ii) a light chain variable region sequence of SEQ ID NO: 19.

### Claim 14

An antibody, or antigen-binding fragment thereof, comprising:
a) a heavy chain comprising a CDRH1 of SEQ ID NO: 24, a CDRH2 of SEQ ID NO: 25, and a CDRH3 of SEQ ID NO: 26; and
b) a light chain comprising a CDRL1 of SEQ ID NO: 21, a CDRL2 of SEQ ID NO: 22, and a CDRL3 of SEQ ID NO: 23.

### Claim 15 (depends on 14)

The antibody of claim 14, comprising:
i) a heavy chain variable region sequence with at least 95% identity to SEQ ID NO: 27; and
ii) a light chain variable region sequence with at least 95% identity to SEQ ID NO: 29.

### Claim 16 (depends on 14)

The antibody of claim 14, comprising:
i) a heavy chain variable region sequence of SEQ ID NO: 27; and
ii) a light chain variable region sequence of SEQ ID NO: 29.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

An antibody, or antigen-binding fragment thereof, that competes with an antibody of any one of claims 1-16 for binding to ENPP1.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The antibody, or antigen-binding fragment thereof, of any one of claims 1-17, wherein the antibody, or antigen-binding fragment thereof, is murine, chimeric or humanized.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The antibody, or antigen-binding fragment thereof, of any one of claims 1-18, wherein the antibody, or antigen-binding fragment thereof, is an intact IgG isotype antibody.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The antibody, or antigen-binding fragment thereof, of any one of claims 1-18, wherein the antibody, or antigen-binding fragment thereof, is an antigen-binding antibody fragment selected from an Fv, an Fav, an F(ab′)2), an Fab′, a dsFv, an scFv, an sc(Fv)2, and a diabody.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The antibody, or antigen-binding fragment thereof, of any one of claims 1-20, wherein the antibody, or antigen-binding fragment thereof, specifically binds to ENPP1.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The antibody, or antigen-binding fragment thereof, of any one of claims 1-21, wherein the antibody, or antigen binding fragment thereof, inhibits ENPP1 activity.

### Claim 23 (depends on 22)

The antibody, or antigen-binding fragments thereof, of claim 22, wherein the antibody is 12-JA-A, 14-O17-A, or 5-H7-A.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The antibody, or antigen-binding fragment thereof, of any one of claims 1-22, wherein the antibody, or antigen-binding fragment thereof, competes with antibody 12-JA-A, or 14-O17-A, or 5-H7-A for binding to ENPP1.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A nucleic acid molecule encoding a heavy chain variable region of an antibody of any one of claims 1-24.

### Claim 26 (depends on 25)

The nucleic acid molecule of claim 25, comprising a sequence that is at least 95% identical to SEQ ID NO: 8, 18, or 28.

### Claim 27 (depends on 25)

The nucleic acid molecule of claim 25, comprising a sequence of SEQ ID NO: 8, 18, or 28.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A nucleic acid molecule encoding a light chain variable region of an antibody of any one of claims 1-25.

### Claim 29 (depends on 28)

The nucleic acid molecule of claim 28, comprising a sequence that is at least 95% identical to SEQ ID NO: 10, 20, or 30.

### Claim 30 (depends on 28)

The nucleic acid molecule of claim 28, comprising a sequence of SEQ ID NO: 10, 20, or 30.

### Claim 31 (depends on 25, 26, 27, 28, 29, 30)

A vector comprising the nucleic acid of any one of claims 25-30.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 31)

A host cell that:
(a) comprises the nucleic acid of any one of claims 25-29;
(b) comprises the vector of claim 31; and/or
(c) expresses the antibody, or antigen-binding fragment thereof, of any one of claims 1-24.

### Claim 33 (depends on 43)

A method of producing an antibody, or antigen-binding fragment thereof, comprising the steps of: (i) culturing the host cell of claim 43 to allow expression of the antibody, or antigen-binding fragment thereof; and (ii) recovering the expressed antibody, or antigen-binding fragment thereof.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A pharmaceutical composition comprising an antibody or antigen-binding fragment thereof of any one of claims 1-24.

### Claim 35 (depends on 34)

A method of treating myocardial infarction in a subject comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 34.

### Claim 36 (depends on 34)

A method of preventing heart failure in a subject comprising administering to the subject the pharmaceutical composition of claim 34.

### Claim 37 (depends on 34)

A method of promoting cardiac wound healing in a subject comprising administering to the subject the pharmaceutical composition of claim 34.

### Claim 38 (depends on 34)

A method of preventing ectopic calcification of cardiac tissue in a subject comprising administering to the subject the pharmaceutical composition of claim 34.

### Claim 39 (depends on 34)

A method of preventing scarring of cardiac tissue in a subject comprising administering to the subject the pharmaceutical composition of claim 34.

### Claim 40 (depends on 34)

A method of preventing dilated cardiomyopathy in a subject comprising administering to the subject the pharmaceutical composition of claim 34.

### Claim 41 (depends on 34)

A method of enhancing cardiac repair in a subject comprising administering to the subject the pharmaceutical composition of claim 34.

### Claim 42 (depends on 34)

A method of preventing cell death of cardiac cells comprising administering to the subject the pharmaceutical composition of claim 34.

### Claim 43 (depends on 34)

A method of preventing release of one or more pro-inflammatory molecules from cardiac myocytes in a subject comprising administering to the subject the pharmaceutical composition of claim 34.

### Claim 44 (depends on 34)

A method of inhibiting ENPP1 activity in a subject comprising administering to the subject the pharmaceutical composition of claim 34.
